Joel Greenblatt · Magic Formula: alta rentabilidad del capital a un EV/EBIT bajo
Is ACADIA Pharmaceuticals Inc. (ACAD) a Joel Greenblatt Stock?
Partial match: either cheap or high-quality, but not both.
59/100
No encaja
2/5 criterios cumplidos
Los criterios de Joel Greenblatt, aplicados a ACAD
EBIT/EV yield ≥ 10%
clave3.1%
ROIC ≥ 25%
clave6.2%
EV/EBIT ≤ 12
32.4x
Gross margin ≥ 30%
91.5%
Cómo se valora ACAD en otras estrategias
Datos financieros en vivo
Cap. mercado
$3.44B
PER (TTM)
9.6x
ROIC (TTM)
6.17%
Margen bruto
91.47%
Otros análisis Joel Greenblatt
Preguntas frecuentes
What is ACAD's Joel Greenblatt fit score?
ACAD scores 59/100 on our Joel Greenblatt fit engine. Partial match: either cheap or high-quality, but not both.
Does Joel Greenblatt actually own ACAD?
Our score is computed from financial fundamentals against Joel Greenblatt's published criteria. We don't claim that Joel Greenblatt personally owns or recommends ACAD.
How often is this score updated?
ACAD's Joel Greenblatt fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Joel Greenblatt posea o recomiende ACAD personalmente.
